Company

IDRx

Biotechnology Research The Limitations of Today’s Precision Cancer Medicines with Highly Potent and Selective Targeted Therapies to Stop Key Tumor Escape Mechanisms and Prolong Response to Therapy. 39 employees

Employees: 39
Contacts: 2
Emails: 2
Phones: 1

www.idrx.com LinkedIn Crunchbase

IDRx Overview

Headquarters: The Limitations of Today’s Precision Cancer Medicines with Highly Potent and Selective Targeted Therapies to Stop Key Tumor Escape Mechanisms and Prolong Response to Therapy.
Website: www.idrx.com
Industry: Biotechnology Research
Employees: 39
Funding: 120.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

to advance the development of this novel treatment for patients in need.

About IDRx

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy.

IDRx Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage
Phone contacts: 1; 25.0% coverage

IDRx Org Chart

Sample employees and titles

Name	Title	Location	Contact
Jessica Anderson Christo	Chief Development Operations Officer	Greater Boston, United States	Email
Jakob Loven, Phd			View
Caridad Mcdonough (Street)	Associate Director, Gmp Quality		View
George Demetri	SVP Experimental Therapeutics	Boston, Massachusetts, United States	Email Phone